Two Lesser-Known AI Telehealth Cases Worth Watching | Seth Brand Tech Care Blog
Back to Blog
AI July 18, 2026 7 min read Seth Brand

Two Lesser-Known AI Telehealth Cases Worth Watching

One case centers on AI-shaped doctor pages. The other centers on fake reviews, hidden terms, and billing issues.

Editorial illustration showing telehealth signup screens, doctor profile cards, and warning indicators

Illustration for this article.

TL;DR

  • Medvi is an AI-powered telehealth startup. Business Insider reported affiliate ads that used doctor pages that appeared AI-generated or repurposed from other people or businesses.
  • The FDA warned Medvi in February 2026 that claims on medvi.io were false or misleading, including claims about compounded semaglutide and tirzepatide.
  • NextMed settled FTC charges in July 2025 and again in December 2025 over misleading prices, fake reviews, hidden costs, and billing and cancellation issues.

I wanted a couple of smaller names here, not the obvious headline cases. Medvi and NextMed are useful because the public record is specific enough to check. One case shows how AI-shaped marketing can blur who is actually behind an offer. The other shows how a telehealth business can get in trouble even without the AI angle when the reviews, prices, and billing practices do not hold up.

Medvi

Business Insider reported in April 2026 that Medvi is an AI-powered telehealth startup with two employees, while also saying the company reported $401 million in revenue and $65 million in profit last year and was projected to reach $1.8 billion in sales this year. Matthew Gallagher, Medvi's founder, told BI that maybe 30% of the company's advertising was through affiliates, and BI said none of the pages it reviewed included prominent disclosures.

BI then reviewed Meta's ad library and found that some affiliates were running ads with doctor pages that appeared to use AI-generated content. BI said the pages included telltale signs like garbled text, and in some cases the pages appeared to have belonged to other people or businesses before being used to market Medvi. BI also reported that at least six purported doctor pages were advertising Medvi's weight-loss drugs and a product for men's sexual performance.

  • BI said one profile, "Dr. Matthew Anderson MD," listed an Angolan phone number and appeared to have previously belonged to a gospel musician.
  • BI said another profile, "Dr. Spencer Langford MD," featured older posts and contact information tied to a clothing store in the Republic of Congo.
  • BI said one Medvi marketer dropped the "MD" after the outlet asked about it, and the same profile photo was used by three other pages advertising Medvi.
  • BI said Medvi-linked ads fell from more than 5,000 active campaigns on Friday to roughly 2,800 by Monday after the outlet raised questions about the pages.

The FDA also sent Medvi a warning letter on February 20, 2026. The letter said the agency reviewed medvi.io in December 2025 and found false or misleading claims about compounded semaglutide and tirzepatide products. The FDA said the site suggested Medvi was the compounder of those drugs when it was not, and it flagged claims such as "Same active ingredient as Wegovy and Ozempic" and "Same active ingredient as Mounjaro and Zepbound."

That is enough for me to treat Medvi as a real case study, not a vibe check. The public record shows an affiliate-heavy ad setup, doctor pages with garbled text or prior identities, an FDA warning letter tied to the product claims on the site, and Medvi being named in a consumer group request for an FTC investigation.

NextMed

NextMed is not the flashy AI case. It is the quieter one. The FTC announced in July 2025 that Southern Health Solutions, doing business as Next Medical and NextMed, agreed to settle charges that it used deceptive cost and weight-loss claims, fake reviews, and fake testimonials to sell GLP-1 weight-loss programs with hidden terms and conditions.

In the FTC's December 2025 final order, the agency said NextMed and its principals had to stop deceptively advertising weight-loss programs and stop using deceptive and unfair billing and cancellation practices. The FTC said the company sold programs with undisclosed costs and membership commitments, made unsubstantiated claims about the weight loss clients achieved, unfairly distorted consumer reviews, failed to process cancellation and refund requests in a timely manner, and failed to obtain express informed consent before charging consumers or making recurring debits.

  • The proposed settlement order required NextMed and its principals to pay $150,000.
  • The FTC said they would be banned from misrepresenting products and reviews.
  • The case centered on GLP-1 weight-loss programs, not on a synthetic AI persona, but the marketing problems were still concrete and well documented.

That is why I included NextMed here. It is not the same type of story as Medvi, but it shows the same core problem from a different angle. The offer looks simple on the front end, then the real terms, review practices, and billing behavior show up later.

Why these belong in the AI folder

Medvi belongs here directly because the public reporting points to AI-generated-looking doctor pages and AI tools used in the company's marketing stack. NextMed belongs here because it shows the surrounding pattern that often sits next to AI hype in health marketing: aggressive claims, hidden costs, fake reviews, and messy cancellation and refund handling.

I am not saying every affiliate ad is a scam or that every telehealth company is the same. I am saying these are two smaller public cases with enough documentation to be worth watching if you are trying to understand how AI-era marketing gets used in the real world.

Sources

This article is consumer-protection and security reporting based on publicly available FTC, FDA, and Business Insider reporting. If you are a party mentioned in this article and believe a factual statement is inaccurate, contact [email protected] with specific corrections and supporting evidence.